vs
Legence Corp.（LGN）与Medpace Holdings, Inc.（MEDP）财务数据对比。点击上方公司名可切换其他公司
Medpace Holdings, Inc.的季度营收约是Legence Corp.的1.0倍（$708.5M vs $708.0M），Medpace Holdings, Inc.净利率更高（19.1% vs -0.1%，领先19.2%），Medpace Holdings, Inc.同比增速更快（32.0% vs 26.2%），Medpace Holdings, Inc.自由现金流更多（$188.1M vs $137.4M）
Legence Corp是一家可持续建筑与脱碳解决方案服务商，主要提供能效优化、楼宇自动化系统设计、可再生能源整合及低碳改造服务，客户覆盖商业、工业、公共机构等领域，核心业务布局北美，助力客户降低运营成本、减少碳排放。
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
LGN vs MEDP — 直观对比
营收规模更大
MEDP
是对方的1.0倍
$708.0M
营收增速更快
MEDP
高出5.8%
26.2%
净利率更高
MEDP
高出19.2%
-0.1%
自由现金流更多
MEDP
多$50.7M
$137.4M
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $708.0M | $708.5M |
| 净利润 | $-576.0K | $135.1M |
| 毛利率 | 20.9% | — |
| 营业利润率 | 5.3% | 21.6% |
| 净利率 | -0.1% | 19.1% |
| 营收同比 | 26.2% | 32.0% |
| 净利润同比 | 46.8% | 15.5% |
| 每股收益（稀释后） | $-0.02 | $4.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LGNMEDP
| Q4 25 | — | $708.5M | ||
| Q3 25 | $708.0M | $659.9M | ||
| Q2 25 | — | $603.3M | ||
| Q1 25 | — | $558.6M | ||
| Q4 24 | — | $536.6M | ||
| Q3 24 | $560.8M | $533.3M | ||
| Q2 24 | — | $528.1M | ||
| Q1 24 | — | $511.0M |
净利润LGNMEDP
| Q4 25 | — | $135.1M | ||
| Q3 25 | $-576.0K | $111.1M | ||
| Q2 25 | — | $90.3M | ||
| Q1 25 | — | $114.6M | ||
| Q4 24 | — | $117.0M | ||
| Q3 24 | $-1.1M | $96.4M | ||
| Q2 24 | — | $88.4M | ||
| Q1 24 | — | $102.6M |
毛利率LGNMEDP
| Q4 25 | — | — | ||
| Q3 25 | 20.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 21.1% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率LGNMEDP
| Q4 25 | — | 21.6% | ||
| Q3 25 | 5.3% | 21.5% | ||
| Q2 25 | — | 20.9% | ||
| Q1 25 | — | 20.3% | ||
| Q4 24 | — | 23.4% | ||
| Q3 24 | 4.8% | 21.1% | ||
| Q2 24 | — | 19.9% | ||
| Q1 24 | — | 20.4% |
净利率LGNMEDP
| Q4 25 | — | 19.1% | ||
| Q3 25 | -0.1% | 16.8% | ||
| Q2 25 | — | 15.0% | ||
| Q1 25 | — | 20.5% | ||
| Q4 24 | — | 21.8% | ||
| Q3 24 | -0.2% | 18.1% | ||
| Q2 24 | — | 16.7% | ||
| Q1 24 | — | 20.1% |
每股收益（稀释后）LGNMEDP
| Q4 25 | — | $4.65 | ||
| Q3 25 | $-0.02 | $3.86 | ||
| Q2 25 | — | $3.10 | ||
| Q1 25 | — | $3.67 | ||
| Q4 24 | — | $3.67 | ||
| Q3 24 | — | $3.01 | ||
| Q2 24 | — | $2.75 | ||
| Q1 24 | — | $3.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $176.0M | $497.0M |
| 总债务越低越好 | $812.6M | — |
| 股东权益账面价值 | $387.9M | $459.1M |
| 总资产 | $2.6B | $2.0B |
| 负债/权益比越低杠杆越低 | 2.10× | — |
8季度趋势，按日历期对齐
现金及短期投资LGNMEDP
| Q4 25 | — | $497.0M | ||
| Q3 25 | $176.0M | $285.4M | ||
| Q2 25 | — | $46.3M | ||
| Q1 25 | — | $441.4M | ||
| Q4 24 | — | $669.4M | ||
| Q3 24 | — | $656.9M | ||
| Q2 24 | — | $510.9M | ||
| Q1 24 | — | $407.0M |
总债务LGNMEDP
| Q4 25 | — | — | ||
| Q3 25 | $812.6M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益LGNMEDP
| Q4 25 | — | $459.1M | ||
| Q3 25 | $387.9M | $293.6M | ||
| Q2 25 | — | $172.4M | ||
| Q1 25 | — | $593.6M | ||
| Q4 24 | — | $825.5M | ||
| Q3 24 | — | $881.4M | ||
| Q2 24 | — | $763.6M | ||
| Q1 24 | — | $671.5M |
总资产LGNMEDP
| Q4 25 | — | $2.0B | ||
| Q3 25 | $2.6B | $1.8B | ||
| Q2 25 | — | $1.6B | ||
| Q1 25 | — | $1.9B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.1B | ||
| Q2 24 | — | $1.9B | ||
| Q1 24 | — | $1.8B |
负债/权益比LGNMEDP
| Q4 25 | — | — | ||
| Q3 25 | 2.10× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $162.1M | $192.7M |
| 自由现金流经营现金流 - 资本支出 | $137.4M | $188.1M |
| 自由现金流率自由现金流/营收 | 19.4% | 26.6% |
| 资本支出强度资本支出/营收 | 3.5% | 0.6% |
| 现金转化率经营现金流/净利润 | — | 1.43× |
| 过去12个月自由现金流最近4个季度 | — | $681.9M |
8季度趋势，按日历期对齐
经营现金流LGNMEDP
| Q4 25 | — | $192.7M | ||
| Q3 25 | $162.1M | $246.2M | ||
| Q2 25 | — | $148.5M | ||
| Q1 25 | — | $125.8M | ||
| Q4 24 | — | $190.7M | ||
| Q3 24 | — | $149.1M | ||
| Q2 24 | — | $116.4M | ||
| Q1 24 | — | $152.7M |
自由现金流LGNMEDP
| Q4 25 | — | $188.1M | ||
| Q3 25 | $137.4M | $235.5M | ||
| Q2 25 | — | $142.4M | ||
| Q1 25 | — | $115.8M | ||
| Q4 24 | — | $183.0M | ||
| Q3 24 | — | $138.5M | ||
| Q2 24 | — | $103.5M | ||
| Q1 24 | — | $147.2M |
自由现金流率LGNMEDP
| Q4 25 | — | 26.6% | ||
| Q3 25 | 19.4% | 35.7% | ||
| Q2 25 | — | 23.6% | ||
| Q1 25 | — | 20.7% | ||
| Q4 24 | — | 34.1% | ||
| Q3 24 | — | 26.0% | ||
| Q2 24 | — | 19.6% | ||
| Q1 24 | — | 28.8% |
资本支出强度LGNMEDP
| Q4 25 | — | 0.6% | ||
| Q3 25 | 3.5% | 1.6% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | — | 1.4% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | — | 1.1% |
现金转化率LGNMEDP
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 2.22× | ||
| Q2 25 | — | 1.65× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | — | 1.32× | ||
| Q1 24 | — | 1.49× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LGN
| Installation And Fabrication | $408.7M | 58% |
| Engineering And Design | $110.9M | 16% |
| Program And Project Management | $101.2M | 14% |
| Maintenance And Service | $87.1M | 12% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
